MedPhab

Photonics Solutions at Pilot Scale for Accelerated Medical Device Development

Photonics technologies have become a key enabler in the realization of modern medical devices with applications ranging from diagnostics to surgical tools and therapeutics. The characteristic nature of both photonics and application fields is high diversity. Consequently, the more widespread use of photonics technologies in scattered ecosystems presents major challenges for both end-user companies and manufacturers. In conjunction with highly regulated validation and production, the timespan from the concept phase to product launch takes years. Addressing these challenges, MedPhab will serve as Europe’s first Pilot Line dedicated to manufacturing, testing, validation and upscaling of new photonics technologies for medical diagnostics enabling accelerated product launch with reduced R&D costs. MedPhab will bring high-quality infrastructure and extensive know-how within easy reach of the SME’s and other European Industry. Globally unique feature of MedPhab is its operation in medical domain setting requirements to meet regulations. The competitive differentiation is the seamless operation between ISO13485 certified companies and RTOs when the single-entry point can serve SMEs operating at different TRLs. Professional customer interface will be operated by staff with extensive experience in the field of medical devices. The technology readiness and MedPhab operation process will be validated by:

1) Use Case Validation program, upscaling and demonstrating the performance of 5 innovative medical diagnostics products;

2) Demo Case Open Calls program enabling early adoption of the technologies by an external user, demonstrating the pilot line services and validating the open-access business model.

AMIRES was involved in the project’s preparatory phase and in the negotiations. Within the project it is responsible for project management and organization of the open calls for pilot customers. Moreover, AMIRES is responsible for the community management platform and business development and exploitation.

• Partners:
  • VTT-TECHNICAL RESEARCH CENTRE OF FINLAND, Finland
  • UNIVERSITY COLLEGE CORK -NATIONAL UNIVERSITY OF IRELAND, CORK, Ireland
  • JOANNEUM RESEARCH FORSCHUNGSGESELLSCHAFT MBH, Austria
  • INTERUNIVERSITAIR MICROELECTRONICA CENTRUM, Belgium
  • CSEM CENTRE SUISSE D’ELECTRONIQUE ET DE MICROTECHNIQUE SA – RECHERCHE ET DEVELOPPEMENT- Switzerland
  • PHILIPS ELECTRONICS NEDERLAND B.V., Netherlands
  • JABIL CIRCUIT AUSTRIA GMBH, Austria
  • SCREENTEC OY, Finland
  • III-V LAB, France
  • STRYKER EUROPEAN OPERATIONS LIMITED, Ireland
  • POLAR ELECTRO OY, Finland
  • RADISENS DIAGNOSTICS LIMITED, Ireland
  • ANTELOPE DX, Belgium
  • GENSPEED BIOTECH GMBH, Austria
  • VIENNALAB DIAGNOSTICS GMBH, Austria
  • STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS- Netherlands
  • EUROPEAN PHOTONICS INDUSTRY CONSORTIUM, France
  • AMIRES, The business innovation management institute, z.u., Czech Republic

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 871345 , project MEDPHAB.